RxDoctor Payments Data

Vren Edrick Manuel, DO

Family Medicine · Largo, FLNPI 1326626284

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 28 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 12 manufacturers, the largest accounting for just 21.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $310, more than ten times the $17 reported in 2023.

$564in general payments, 2019–2025

Across 28 payments — averaging $20.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$122
  • Exact Sciences$99
  • AstraZeneca$66
  • Lilly USA, LLC$63
  • Boehringer Ingelheim$45
  • AbbVie$31
  • plus $138 from 6 others

What the payments were for

  • Food & beverage$564100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$564 in reported general payments places this provider in the 55th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida →

Medicare billing

Part B allowed, 2024
$8,662
Medicare patients
61
Services billed
162

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RybelsusSemaglutide23$29,372
EliquisApixaban13$20,862
Atorvastatin Calcium91$906
Glipizide ErGlipizide27$547
Levothyroxine Sodium48$404
Gabapentin16$393
Albuterol Sulfate HfaAlbuterol Sulfate11$354
Rosuvastatin Calcium21$289
Pantoprazole Sodium23$259
Lisinopril34$213
Omeprazole15$199
Losartan Potassium25$195
Metoprolol Succinate15$152
Carvedilol17$146
Metformin Hcl23$140

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus$14$29,37223 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Largo

See the full list for Florida →

Where these figures come from

Is this you, or does something look wrong? →